Adalvo and Aristo Pharma proudly announce the successful launch of Pregabalin Prolonged Release Tablets in Germany, solidifying their position as the first to introduce this innovative medication in the European Union.
This product, indicated for treating Neuropathic Pain, is set to enhance patient adherence through its unique prolonged-release formulation. Pregabalin Prolonged Release Tablets offer a distinctive advantage by reducing the daily administration requirements, addressing a crucial aspect of patient convenience and treatment compliance. The extended-release feature is designed to optimise the therapeutic benefits of the medication, providing a valuable option for individuals managing Neuropathic pain.
With a global annual sales figure of $2065Mn in 2023, as reported by IQVIA, Pregabalin Prolonged Release Tablets have demonstrated significant market impact, underscoring the immense potential of this product.
Anil Okay, CEO of Adalvo, remarks, "Our partnership with Aristo Pharma represents a significant milestone in our commitment to advancing healthcare. Together, we are proud to introduce this innovative medication to market."
Christian Jaaks, CEO of Aristo Pharma, states, 'Our collaboration with Adalvo exemplifies our shared commitment to innovation and patient-centric healthcare. We are confident this partnership will bring positive outcomes for patients in Germany and beyond.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 17 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Aristo Pharma
Aristo Pharma GmbH, established in 2008, is one of the fastest growing pharmaceutical companies in Europe covering most of the European markets.
As a vertically integrated company, Aristo Pharma is operating five state of the art manufacturing facilities in Germany and Spain.
With its approx. 1,600 highly motivated employees and its 13 sales and marketing locations, Aristo Pharma promotes high standard pharmaceutical products and medical devices to doctors, pharmacies and wholesalers across Europe.